| scholarly article | Q13442814 |
| P50 | author | Helio S Sader | Q63144492 |
| Ronald N Jones | Q120908182 | ||
| P2093 | author name string | David J Farrell | |
| Paul R Rhomberg | |||
| P2860 | cites work | Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia | Q22241905 |
| Aminoglycosides: activity and resistance | Q33548221 | ||
| Inhaled antibiotics for lower airway infections. | Q33640488 | ||
| The efficacy and safety of arbekacin and vancomycin for the treatment in skin and soft tissue MRSA infection: preliminary study | Q37192126 | ||
| Defining, treating and preventing hospital acquired pneumonia: European perspective | Q37319452 | ||
| Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy | Q37656243 | ||
| Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia | Q37769547 | ||
| Prevalence of β-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010). | Q41441191 | ||
| In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center. | Q41976880 | ||
| New options of antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa | Q42204159 | ||
| Pharmacokinetics of arbekacin in bronchial epithelial lining fluid of healthy volunteers | Q42208485 | ||
| Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: a multi-institutional study | Q44609459 | ||
| Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients | Q44850427 | ||
| The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infection. | Q50958954 | ||
| Nebulized Ceftazidime and Amikacin in Ventilator-associated Pneumonia Caused byPseudomonas aeruginosa | Q61708478 | ||
| [Antibacterial activities of arbekacin, a new aminoglycoside antibiotic, against methicillin-cephem-resistant Staphylococcus aureus] | Q69337732 | ||
| Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis | Q81435842 | ||
| Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia | Q83473464 | ||
| Clinical efficacy of arbekacin for Gram-negative bacteria | Q84342595 | ||
| Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012 | Q87444358 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pneumonia | Q12192 |
| hospitalization | Q3140971 | ||
| P304 | page(s) | 3263-3270 | |
| P577 | publication date | 2015-03-23 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia | |
| P478 | volume | 59 |
| Q38851189 | Aminoglycosides: An Overview |
| Q28468292 | Anti-staphylococcal activity resulting from epithelial lining fluid (ELF) concentrations of amikacin inhale administered via the pulmonary drug delivery system |
| Q40913492 | Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem |
| Q41695620 | Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015. |
| Q26751041 | Clinical Usefulness of Arbekacin |
| Q40852571 | Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies |
| Q36434386 | Detecting 16S rRNA Methyltransferases in Enterobacteriaceae by Use of Arbekacin |
| Q40401622 | Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused by Pseudomonas aeruginosa |
| Q37538764 | Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa. |
| Q89529481 | Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms |
| Q39674263 | In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates |
| Q38783043 | Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia. |
| Q92641224 | Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation Solution |
| Q52670587 | Resistance Trends and Treatment Options in Gram-Negative Ventilator-Associated Pneumonia. |
Search more.